GB2441581B - Compositions and methods for the treatment of muscle wasting - Google Patents

Compositions and methods for the treatment of muscle wasting

Info

Publication number
GB2441581B
GB2441581B GB0616790A GB0616790A GB2441581B GB 2441581 B GB2441581 B GB 2441581B GB 0616790 A GB0616790 A GB 0616790A GB 0616790 A GB0616790 A GB 0616790A GB 2441581 B GB2441581 B GB 2441581B
Authority
GB
United Kingdom
Prior art keywords
compositions
treatment
methods
muscle wasting
wasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0616790A
Other versions
GB2441581A (en
GB0616790D0 (en
Inventor
Roderic M K Dale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oligos Etc Inc
Original Assignee
Oligos Etc Inc
Lakewood-Amedex Inc
Lakewood Amedex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB2005100777302A external-priority patent/CN100393320C/en
Application filed by Oligos Etc Inc, Lakewood-Amedex Inc, Lakewood Amedex Inc filed Critical Oligos Etc Inc
Priority claimed from PCT/US2006/025657 external-priority patent/WO2008005002A1/en
Publication of GB0616790D0 publication Critical patent/GB0616790D0/en
Publication of GB2441581A publication Critical patent/GB2441581A/en
Application granted granted Critical
Publication of GB2441581B publication Critical patent/GB2441581B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0616790A 2005-06-24 2006-06-30 Compositions and methods for the treatment of muscle wasting Expired - Fee Related GB2441581B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100777302A CN100393320C (en) 2005-06-24 2005-06-24 Oligonucleotide medicine for treating myophagism
PCT/US2006/025657 WO2008005002A1 (en) 2006-06-30 2006-06-30 Compositions and methods for the treatment of muscle wasting

Publications (3)

Publication Number Publication Date
GB0616790D0 GB0616790D0 (en) 2006-10-04
GB2441581A GB2441581A (en) 2008-03-12
GB2441581B true GB2441581B (en) 2011-01-19

Family

ID=39106232

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0616790A Expired - Fee Related GB2441581B (en) 2005-06-24 2006-06-30 Compositions and methods for the treatment of muscle wasting

Country Status (1)

Country Link
GB (1) GB2441581B (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035032A1 (en) * 1992-05-22 1995-12-28 The Scripps Research Institute SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES
WO2003002739A1 (en) * 2001-05-24 2003-01-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2004031350A2 (en) * 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
US20050020541A1 (en) * 2001-10-30 2005-01-27 Reinhold Tacke Silicon compounds
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
WO2006086667A2 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035032A1 (en) * 1992-05-22 1995-12-28 The Scripps Research Institute SUPPRESSION OF NUCLEAR FACTOR-kB DEPENDENT PROCESSES USING OLIGONUCLEOTIDES
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
WO2003002739A1 (en) * 2001-05-24 2003-01-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof
US20050020541A1 (en) * 2001-10-30 2005-01-27 Reinhold Tacke Silicon compounds
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2004031350A2 (en) * 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
WO2006086667A2 (en) * 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
American Journal of Physiology - Cell Physiology (2006); Vol 291, pp C538-C545, "Gene silencing of myostatin in different...", Sato et al *
Expert Opinion on Emerging Drugs (2004); Vol 9, pp 345-361, "Emerging drugs for sarcopenia:age related muscle wasting", Lynch *

Also Published As

Publication number Publication date
GB2441581A (en) 2008-03-12
GB0616790D0 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
EP1737482A4 (en) Compositions and methods for treating diseases
ZA200704677B (en) Compositions and methods for the treatment of autism
IL196465A0 (en) Compositions and methods for the treatment of mucositis
IL186973A0 (en) Compositions and methods for treatment for neoplasms
IL191072A0 (en) Therapeutic compositions and methods
IL186963A0 (en) Methods and compositions for treating pain
EP1890712A4 (en) Compositions and methods for treating pain
EP1814575A4 (en) Methods and compositions for treating conditions
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
IL198723A0 (en) Methods and compositions for therapeutic treatment
GB0522460D0 (en) Composition and method for the treatment of avian influenza
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
EP2124968A4 (en) Compositions and methods for the treatment of muscle wasting
ZA200804500B (en) Methods and compositions for the treatment of gastro-intestinal disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1937075A4 (en) Synergistic composition and method of use
EP1720563A4 (en) Methods and compositions for the treatment of inflammation
EP1740221A4 (en) Methods and compositions for the treatment of polycystic diseases
EP1904088A4 (en) Compositions and methods for the treatment of cancer
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: OLIGOS ETC, INC.

Free format text: FORMER APPLICANT(S): DALE, RODERIC M K

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20100729 AND 20100804

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20220630